Our AI-native genomics platform processes billions of base pairs to accelerate drug discovery, from target identification to clinical candidate in months, not years.
What We Do
Our proprietary models analyze genetic data at unprecedented scale, uncovering patterns invisible to traditional methods.
Whole-genome sequencing at 30x coverage with 99.99% accuracy. Processed through our proprietary alignment pipeline.
Machine learning models trained on 4.2M genomes identify novel drug targets with validated biological relevance.
Generative chemistry models design small molecules optimized for binding affinity, ADMET properties, and synthesizability.
Multi-omics integration reveals biomarker signatures for patient stratification and companion diagnostic development.
Optimized guide RNA design with off-target prediction. 94% editing efficiency across tested cell lines.
Real-world evidence platform connecting genomic profiles with clinical outcomes across 200+ trial sites.
Our Platform
Traditional bioinformatics tools weren't designed for the scale of modern genomics. Our cloud-native platform processes whole-genome datasets that would crash legacy systems.
From raw FASTQ files to actionable insights, our end-to-end pipeline reduces analysis time from weeks to hours.
Genomes Analyzed
Drug Candidates
Cost Reduction
Research Focus
Identifying causal variants for 7,000+ rare diseases using multi-ethnic cohort analysis and novel statistical methods.
Predicting neoantigen presentation and T-cell receptor specificity for personalized cancer immunotherapy design.
Genome-wide association studies combined with proteomics to identify novel targets for Alzheimer's and Parkinson's.
Designing gene circuits and metabolic pathways for cell therapy manufacturing and bioproduction optimization.
What Leaders Say
Helix's platform identified a novel kinase target for our AML program that our internal team missed. We're now in IND-enabling studies.
What used to take our bioinformatics team 6 weeks now runs in under 4 hours. The accuracy improvements are equally remarkable.
The rare disease diagnostic yield improved from 32% to 61% after integrating Helix's variant classification engine. Game-changing.
Join 200+ research institutions and pharma companies using Helix to accelerate genomic discovery.
Request Demo